Plasminogen Activation in Bullous Pemphigoid Immunohistology Reveals Urokinase Type Plasminogen Activator, Its Receptor and Plasminogen Activator Inhibitor Type-2 in Lesional Epidermis

References

• Morioka S., Singe H. S., Hashimoto K., Jensen P. J., Lazarus G. S. Epidermal plasminogen activator: characterization, regulatory mechanisms and possible role in skin disease. Rev. Adv. Dermatol. 1986; 7: 53–67
   Google Scholar
• Lazarus G. S., Jensen P. J. Plasminogen Activators in Epithelial Biology. Sem. Thromb. Hemost. 1991; 17: 210–216
   Google Scholar
• Stopelli M. P., Tacchetti C., Cubellis M. V., Corti A., Hearing V. J., Cassani G., et al. Autocrine Saturation of Pro‐Urokinase Receptors on Human A431 Cells. Cell. 1986; 45: 675–684
   Google Scholar
• Blasi F. Urokinase and Urokinase Receptor: A Paracrine/Autocrine System Regulating Cell Migration and Invasiveness. Bioessays. 1993; 15: 105–111
   PubMed Web of Science ®Google Scholar
• Ellis V., Behrendt N., Danô K. Plasminogen Activation by Receptor‐bound Urokinase. J. Biol. Chem. 1991; 266: 12752–12758
   PubMed Web of Science ®Google Scholar
• Saksela O. Plasminogen activation and regulation of pericellular proteolysis. Biochim Biophys Acta. 1985; 823: 35–65
   PubMed Web of Science ®Google Scholar
• Pöllänen J., Stephens R. W., Vaheri A. Directed Plasminogen Activation at the Surface of Normal and Malignant Cells. Adv. Cancer Res. 1991; 57: 273–328
   PubMed Web of Science ®Google Scholar
• Jensen P. J., Rodeck U. Autocrine/Paracrine Regulation of Keratinocyte Urokinase Plasminogen Activator Through the TGF‐dEGF Receptor. J. Cell Phys. 1993; 155: 333–339
   Google Scholar
• Reinartz J., Batrla R., Boukamp P., Fusenig N. E., Kramer M. D. Binding and Activation of Plasminogen at the Surface of Human Keratinocytes. Exp. Cell Res. 1993; 208: 197–208
   Google Scholar
• Hashimoto K., Wan T. ‐C., Baird J., Lazarus G. S., Jensen P. J. Characterization of Keratinocyte Plasminogen Activator Inhibitor and Demonstration of the Prevention of Pemphigus IgG Induced Acantholysis by a Purified Plasminogen Activator Inhibitor. J. Invest. Dermatol. 1989; 92: 310–315
   PubMedGoogle Scholar
• Jensen P. J., Baird J. L., Morioka S., Lessin S., Lazarus G. S. Epidermal Plasminogen Activator is Abnormal in Cutaneous Lesions. J. Invest. Dermatol. 1988; 90: 777–782
   PubMed Web of Science ®Google Scholar
• Baird J., Lazarus G. S., Belin D., Vassalli J. ‐D., Busso N., Gubler P., et al. mRNA for Tissue‐Type Plasminogen Activator Is Present in Lesional Epidermis from Patients with Psoriasis, Pemphigus, or Bullous Pemphigoid, But Is Not Detected in Normal Epidermis. J. Invest. Dermatol. 1990; 95: 548–552
   Google Scholar
• Burge S. M., Cederholm‐Williams S. A., Garrod D. R., Ryan T. J. Cell adhesion in Hailey‐Hailey disease and Darier's disease: immunocytological and explant‐tissue‐culture studies. Br. J. Dermatol. 1991; 125: 426–435
   Google Scholar
• Bruge S. M., Ryan T. J., Cederholm‐Williams S. A. Darier's disease: an immunohistological study using antibodies to proteases. Br. J. Dermatol. 1989; 121: 613–621
   Google Scholar
• Hashimoto K. H., Jensen P. J., Lazarus G. S., Morioka S., Singer K. H. In vitro Studies of Acantholysis of Keratinocytes Induced by Pemphigus Antibody. Immunol. Serol. 1989; 46: 277–290
   Google Scholar
• Korman N. J. Bullous Pemphigoid. Dermatol Clin. 1993; 11: 483–498
   Google Scholar
• Lauharanta J., Salonen E. ‐M., Vaheri A. Plasmin‐like Proteinase Associated with High Molecular Weight Complexes in Blister Fluid of Bullous Pemphigoid. Acta. Derm. Venereol (Stockh.). 1989; 69: 527–529
   Google Scholar
• Kramer M. D., Reinartz J. The Autoimmune Blistering Skin Disease Bullous Pemphigoid The Presence of Plasmin/alpha, ‐antiplasmin Complexes in Skin Blister Fluid Indicates Plasmin Gcneration in Lesional Skin. J. Clin. Invest. 1993; 92: 978–983
   PubMed Web of Science ®Google Scholar
• Gissler M., Simon M. M., Kramer M. D. Enhanced association of plasminogen/plasmin with lesional epidermis of bullous pemphigoid. Br. J. Dermatol. 1992; 121: 272–277
   Google Scholar
• Vennning V. A., Wojnarowska F., Cederholm‐Williams S. An immunohistochemical study of the distribution of plasminogen and plasminogen activators in bullous pemphigoid. Clin. Exp. Dermatol. 1993; 18: 119–12321
   Google Scholar
• Wilkinson J. E., Smith C. A., Suter M. M., Falchek W., Lewis R. M. Role of Plasminogen Activator in Pemphigus Vulgaris. Am. J. pathol. 1989; 134: 561–569
   Google Scholar
• Jordon R. E., Kawana S., Fritz K. A. Immunopathologic Mechanism in Pemphigus and Bullous Pemphigoid. J. Invest. Dermatol. 1985; 85: 72s–78s
   Google Scholar
• Grondahl‐Hansen J., Lund L. R., Ralfkiaer E., Ottevanger V., Danô K. Urokinase‐ and Tissue‐Type Plasminogen Activators in Keratinocytes During Wound Reepithelialization. In Vivo. J. Invest. Dermatol. 1988; 90: 790–795
   PubMed Web of Science ®Google Scholar
• Romer J., Lund L. R., Eriksen J., Ralfkiaer E., Zeheb R., Gelehrter T. D., et al. Differential Expression of Urokinase‐Type Plasminogen Activator and Its Type‐1 Inhibitor During Healing of Mouse Skin Wounds. J. Invest. Dermatol. 1991; 97: 803–811
   Google Scholar
• Romer J., Lund L. R., Eriksen J., Pyke C., Danô K. The Receptor for Urokinase‐type Plasminogen Activator is expressed by Keratinocytes at the Leading Edge During Reepithelialization of Mouse Skin Wounds. J. Invest. Dermatol. 1994; 102: 519–522
   PubMedGoogle Scholar
• Schaefer B. M., Maier K., Eickhoff U., Todd R. F., Kramer M. D. Plasminogen activation in Healing Human Wounds. Am. J. Pathol. 1994; 144: 1269–1280
   Google Scholar
• Gissler M., Frank R., Kramer M. D. Immunohistochemical characterization of the Plasminogen activator system in psoriatic epidermis. Br. J. Dermatol. 1993; 128: 612–218
   Google Scholar
• Kramer M. D., Vettel U., Schmitt M., Reinartz J., Brunner G., Meissauer A. Monoclonal antibodies against plasminogen activators and plasmin(ogen). Fibrinolysis. 1992; 6: 103–111
   Google Scholar
• Foekens J. A., Buessecker F., Peters H. A., Krainick U., van Putten W. L. J., Look M. P., et al. Plasminogen Activator Inhibitor‐2: Prognostic Relevance in 1012 Patients with Primary Breast Cancer. Cancer Res. 1995; 55: 1423–1427
   PubMed Web of Science ®Google Scholar
• Osada H., Yamada C., Miwa K., Kono T., Oh‐hira M. An Assay System for the Modulators of Plasminogen Activation on the Cell Surface. Thromb. Res. 1991; 62: 519–530
   Google Scholar
• Burge S. M., Marshall J. M., Cederholm‐Williams S. A. Plasminogen binding sites in normal human skin. Br. J. Dermatol. 1992; 126: 35–41
   Google Scholar
• Hibino T., Izaki S., Ohkuma M., Kon S., Thorsen S., Astedt B. Epidermal plasminogen activator inhibitor (PAI) is immunologically identical to placental‐type PAI‐2. FEBS Letters. 1988; 231: 202–206
   Google Scholar
• Lyons‐Giordano B., Loskutoff D., Chen C. ‐S., Lazarus G., Keeton M., Jensen P. J. Expression of plasminogen activator inhibitor type 2 in normal and psoriatic epidermis. Histochemistry. 1994; 101: 105–112
   Google Scholar
• Tamai K., Sawamura D., Choi Do H. Y., Li K., Uitto J. Molecular Biology of the 230‐kD Bullous Pemphigoid Antigen. Dermatology. 1994; 189(suppl. 1)27–33
   Google Scholar
• Stanley J. R. Cell Adhesion Molecules as Targets of Autoantibodies in Pemphigus and pemphigoid, Bullous Diseases Due to defective Epidermal Cell Adhesion. Adv. Immunol. 1992; 53: 291–325
   Google Scholar
• Labib R. S., Anhalt G. J., Patel H. P., Mutasim D. F., Diaz L. A. Molecular heterogeneity of the bullous pemphigoid antigens as detected by immunoblotting. J. Immunol. 1986; 136: 1231–1235
   PubMed Web of Science ®Google Scholar
• Takamori K., Yoshiike T., Morioka S., Ogawa H. The role of proteases in the pathogenesis of bullous dermatoses. Int. J. Dermatol. 1988; 21: 533–539
   Google Scholar